Nobelpharma Co Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Nobelpharma Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013961
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
NobelPharma Co Ltd (NobelPharma) is a pharmaceutical company which develops medicines for rare diseases and unmet medical needs. The Company’s pipeline products include NPC-07, NPC-09, NPC-12, NPC-14, NPC-15, NPC-16, NPC-17 and NPC-18. It offers its products in the therapeutic areas of oncology, metabolic diseases; neurology, genetic disorders, women’s health and respiratory. NobelPharma conducts research and development of drugs under categories such as orphan drugs (drugs for rare medical conditions), off-label drug, medicines used for additional efficacy, and pediatric pharmaceuticals. The company has a distribution network which includes Nippon Shinyaku Co., Ltd., Fuji Pharma Co., Ltd and Eisai Co., Ltd. NobelPharma is headquartered in Tokyo, Japan.

Nobelpharma Co Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Nobelpharma Enters into Co-Promotion with ASKA Pharma and Medipal 10
Licensing Agreements 11
NobelPharma Enters into Licensing Agreement with Osaka University 11
NobelPharma Enters into Licensing Agreement with Savara 12
NobelPharma Enters into Licensing Agreement with Serendex Pharma 13
SRI International Enters into Licensing Agreement with Nobelpharma 14
Eisai To Enter Into Licensing Agreement With Nobelpharma For Antineoplastic Agent Gliadel 7.7Mg Implant 15
NobelPharma Enters Into Licensing Agreement With Pfizer For Sirolimus 16
NobelPharma Enters Into Licensing Agreement With Clinigen For Foscavir 17
Nobelpharma Co Ltd – Key Competitors 18
Nobelpharma Co Ltd – Key Employees 19
Nobelpharma Co Ltd – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Product Approvals 22
Nov 11, 2016: Ultragenyx Announces Withdrawal of Marketing Authorization Application for Aceneuramic Acid Prolonged Release (Ace-ER) in the European Union 22
Clinical Trials 23
Jul 27, 2016: Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Aceneuramic Acid Extended Release (Ace-ER) in GNE Myopathy 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Nobelpharma Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Nobelpharma Enters into Co-Promotion with ASKA Pharma and Medipal 10
NobelPharma Enters into Licensing Agreement with Osaka University 11
NobelPharma Enters into Licensing Agreement with Savara 12
NobelPharma Enters into Licensing Agreement with Serendex Pharma 13
SRI International Enters into Licensing Agreement with Nobelpharma 14
Eisai To Enter Into Licensing Agreement With Nobelpharma For Antineoplastic Agent Gliadel 7.7Mg Implant 15
NobelPharma Enters Into Licensing Agreement With Pfizer For Sirolimus 16
NobelPharma Enters Into Licensing Agreement With Clinigen For Foscavir 17
Nobelpharma Co Ltd, Key Competitors 18
Nobelpharma Co Ltd, Key Employees 19
Nobelpharma Co Ltd, Other Locations 21

★海外企業調査レポート[Nobelpharma Co Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • PetroNeft Resources plc (P8ET):石油・ガス:M&Aディール及び事業提携情報
    Summary PetroNeft Resources Plc (PetroNeft) is an upstream oil and gas company. It carries out exploration, development and production of oil and natural gas. The company mainly focuses on oil rich Western Siberia zone in Russia. PetroNeft’s asset base comprises of 50% interest each in License 61 an …
  • Evox Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Evox Therapeutics Ltd (Evox Therapeutics) is a biotechnology company focused on harnessing and engineering the natural delivery capabilities of exosomes, to develop novel medicines for various diseases. Its development pipeline is focused in the therapeutic areas of inflammatory, immune dise …
  • Audentes Therapeutics Inc (BOLD):企業の財務・戦略的SWOT分析
    Summary Audentes Therapeutics Inc (Audentes) is a biotechnology company. It focuses on the development and commercialization of gene therapy products for rare diseases. The company’s pipeline products include AT132, intended for the treatment of X-linked myotubular myopathy; AT982, for the treatment …
  • Pharming Group NV (PHARM):製薬・医療:M&Aディール及び事業提携情報
    Summary Pharming Group NV (Pharming) is a specialty pharmaceutical company which develops nutritional products for the treatment of genetic diseases and unmet medical needs. The company’s flagship product, Ruconest (Rhucin in non-European territories) is a recombinant human C1 inhibitor approved for …
  • Central Japan Railway Company:企業の戦略・SWOT・財務情報
    Central Japan Railway Company - Strategy, SWOT and Corporate Finance Report Summary Central Japan Railway Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Sanofi SA:企業の戦略・SWOT・財務情報
    Sanofi SA - Strategy, SWOT and Corporate Finance Report Summary Sanofi SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Syntel, Inc.:戦略・SWOT・企業財務分析
    Syntel, Inc. - Strategy, SWOT and Corporate Finance Report Summary Syntel, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Shapoorji Pallonji & Co Pvt Ltd:企業の戦略的SWOT分析
    Shapoorji Pallonji & Co Pvt Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Navitas Limited (NVT):企業の財務・戦略的SWOT分析
    Navitas Limited (NVT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Air Transport Services Group, Inc.:戦略・SWOT・企業財務分析
    Air Transport Services Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Air Transport Services Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Livzon Pharmaceutical Group Co Ltd (000513):企業の財務・戦略的SWOT分析
    Summary Livzon Pharmaceutical Group Co Ltd (Livzon) a subsidiary of Joincare Pharmaceutical Group Industry Co Ltd, is a pharmaceutical company which is engaged in developing, manufacturing and distributing pharmaceutical products. The company provides preparation drug products, bulk medicines and in …
  • A2A SpA (A2A):企業の財務・戦略的SWOT分析
    A2A SpA (A2A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • DePuy Synthes Inc:企業の戦略的SWOT分析
    DePuy Synthes Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Willis Lease Finance Corporation (WLFC):企業の財務・戦略的SWOT分析
    Willis Lease Finance Corporation (WLFC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Dana Petroleum Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Dana Petroleum Ltd (Dana), a wholly-owned subsidiary of Korea National Oil Corp (KNOC), is an upstream oil and gas company. It explores, develops and produces oil and gas from its assets in the Europe and the Middle East. The company has interests and operations in the UK, the Netherlands, D …
  • Heiwa Real Estate Co Ltd:企業の戦略・SWOT・財務情報
    Heiwa Real Estate Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Heiwa Real Estate Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Michael Hill International Ltd (MHJ):企業の財務・戦略的SWOT分析
    Michael Hill International Ltd (MHJ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Vistin Pharma AS (VISTIN)-製薬・医療分野:企業M&A・提携分析
    Summary Vistin Pharma AS (Vistin), a subsidiary of Vistin Pharma ASA is a healthcare company that produces and supplies solid dosage forms and active pharmaceutical ingredients. The company’s products include metformin, an API for the treatment of diabetes II; opioids, an analgesics and antitussive; …
  • GE Healthcare:企業のM&A・事業提携・投資動向
    GE Healthcare - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's GE Healthcare Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Nestle Purina PetCare Company:企業の戦略・SWOT・財務情報
    Nestle Purina PetCare Company - Strategy, SWOT and Corporate Finance Report Summary Nestle Purina PetCare Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆